Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Ipsen (EPA: IPN)

 
IPN Technical Analysis
2
As on 1st Nov 2017 IPN Share Price closed @ 104.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 99.11 & Strong Sell for SHORT-TERM with Stoploss of 113.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IPN Share Price

Open 104.00 Change Price %
High 105.75 1 Day 0.95 0.92
Low 103.95 1 Week 0.00 0.00
Close 104.75 1 Month -9.55 -8.36
Volume 65090 1 Year 43.44 70.85
52 Week High 129.85 | 52 Week Low 61.12
 
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
VK 4.72 0.43%
ALALO 0.04 0.00%
CS 26.31 1.47%
TEC 67.40 0.40%
ACA 14.98 0.00%
ALAUP 0.20 -13.04%
 
EPA France Top Gainers Stocks
MLFCI 0.31 34.78%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
ALFRE 1.81 25.69%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
 
EPA France Top Losers Stocks
MLROU 6.37 -34.19%
MLLEA 0.61 -23.75%
ALAUP 0.20 -13.04%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
MLFXO 3.79 -9.98%
TONN 1.20 -9.77%
ALCLS 26.88 -9.22%
RUSAL 10.00 -9.09%
ALEUP 0.20 -9.09%
 
 
IPN
Daily Charts		 IPN
Intraday Charts		 Whats New @
Bazaartrend		 IPN
Free Analysis
 
IPN Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE106.42
RESISTANCE105.73
SUPPORT103.77
SUPPORT103.08
SUPPORT0.00
SUPPORT0.00
 
IPN Target for Month June
Share
4th UP TARGET137.92
3rd UP TARGET127.07
2nd UP TARGET120.37
1st UP TARGET113.66
1st DOWN TARGET94.54
2nd DOWN TARGET87.83
3rd DOWN TARGET81.13
4th DOWN TARGET70.28
 
IPN Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
IPN Target for Year 2021
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website >
 
IPN Address
IPN
 65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
 
IPN Latest News
 
Your Comments and Response on Ipsen
 
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The companyÂ’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service